Related Experiment Videos
Wwox and Ap2gamma expression levels predict tamoxifen response
Gulnur Guler1, Dimitrios Iliopoulos, Nilufer Guler
1Department of Pathology, Hacettepe University, Ankara, Turkey. gguler@hacettepe.edu.tr
Summary
Reduced Wwox and increased Ap2gamma expression predict tamoxifen resistance in breast cancer. These biomarkers may offer superior prediction of treatment response compared to progesterone receptor (PR) and Her2, especially in high-risk patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tamoxifen is a crucial endocrine therapy for estrogen receptor-positive breast cancer.
- Tamoxifen resistance remains a significant clinical challenge, necessitating identification of novel predictive biomarkers.
- Understanding the molecular mechanisms underlying tamoxifen resistance is vital for improving patient outcomes.
Purpose of the Study:
- To assess the expression of Wwox, Wwox-interacting proteins (Ap2alpha, Ap2gamma), and their downstream targets (Her2, PrkaRIalpha) in breast cancer tissues.
- To determine the association of these protein expression levels with tamoxifen resistance.
- To investigate the hypothesis that cytoplasmic sequestration of Wwox interactors influences tamoxifen response.
Main Methods:
- Immunohistochemical staining was performed on tissue sections from 51 tamoxifen-sensitive and 38 tamoxifen-resistant breast cancers.
- Expression levels of Wwox, Ap2alpha, Ap2gamma, ErbB4, Her2, PrkaRIalpha, and progesterone receptor (PR) were quantified.
- Statistical analyses were conducted to correlate protein expression with tamoxifen resistance and clinical features.
Main Results:
- Loss of PR, reduced Wwox expression, and high expression of PrkaRIalpha, Ap2gamma, and Her2 were significantly associated with tamoxifen resistance.
- Wwox, PrkaRIalpha, Ap2gamma, and ErbB4 were identified as independent predictors of tamoxifen resistance in multivariate analysis.
- Reduced Wwox outperformed PR in predicting resistance in high-risk patients, while nuclear Ap2gamma was superior to Her2 in low-risk patients.
Conclusions:
- The study identified complex interrelationships among the assessed marker proteins in vivo.
- Wwox and Ap2gamma show promise as novel biomarkers for predicting tamoxifen response, potentially surpassing PR and Her2.
- These findings suggest new avenues for predicting tamoxifen treatment efficacy and developing targeted therapies for breast cancer.
